ALNYLAM PHARMACEUTICALS, INC. - FORM 10-K - EX-23.2 - EX-23.2 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS OF REGULUS THERAPEUTICS INC. - February 26, 2010

Attached files

file filename
10-K - ALNYLAM PHARMACEUTICALS, INC. - ALNYLAM PHARMACEUTICALS, INC.b78674e10vk.htm
EX-21.1 - EX-21.1 SUBSIDIARIES OF THE REGISTRANT - ALNYLAM PHARMACEUTICALS, INC.b78674exv21w1.htm
EX-31.2 - EX-31.2 SECTION 302 CERTIFICATION OF THE VICE PRESIDENT OF FINANCE AND TREASURER - ALNYLAM PHARMACEUTICALS, INC.b78674exv31w2.htm
EX-99.1 - EX-99.1 REGULUS THERAPEUTICS INC.'S FINANCIAL STATEMENTS - ALNYLAM PHARMACEUTICALS, INC.b78674exv99w1.htm
EX-32.2 - EX-32.2 SECTION 906 CERTIFICATION OF THE VICE PRESIDENT OF FINANCE AND TREASURER - ALNYLAM PHARMACEUTICALS, INC.b78674exv32w2.htm
EX-23.1 - EX-23.1 CONSENT OF PRICEWATERHOUSECOOPERS LLP - ALNYLAM PHARMACEUTICALS, INC.b78674exv23w1.htm
EX-31.1 - EX-31.1 SECTION 302 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - ALNYLAM PHARMACEUTICALS, INC.b78674exv31w1.htm
EX-32.1 - EX-32.1 SECTION 906 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - ALNYLAM PHARMACEUTICALS, INC.b78674exv32w1.htm
EX-10.16 - EX-10.16 2010 ANNUAL INCENTIVE PROGRAM - ALNYLAM PHARMACEUTICALS, INC.b78674exv10w16.htm
EX-10.39 - EX-10.39 COLLABORATION AGREEMENT ENTERED INTO AS OF OCTOBER 29, 2009 - ALNYLAM PHARMACEUTICALS, INC.b78674exv10w39.htm
EX-10.40 - EX-10.40 FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT ENTERED INTO AS OF NOVEMBER 2, 2009 - ALNYLAM PHARMACEUTICALS, INC.b78674exv10w40.htm
EX-10.9 - EX-10.9 FORMS OF INCENTIVE STOCK OPTION AGREEMENT AND NONSTATUTORY STOCK OPTION AGREEMENT - ALNYLAM PHARMACEUTICALS, INC.b78674exv10w9.htm
Exhibit 23.2
Consent of Ernst & Young LLP, Independent Auditors of Regulus Therapeutics Inc.
We consent to the use of our report dated February 26, 2010, with respect to the financial statements of Regulus Therapeutics Inc. incorporated by reference into the Registration Statements (Form S-3 Nos. 333-138586, 333-131233, 333-129905, 333-140076 and Form S-8 Nos. 333-127450, 333-116151, 333-148114, 333-157633) and related Prospectus of Alnylam Pharmaceuticals, Inc. included in Alnylam Pharmaceuticals, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2009.
/s/ Ernst & Young LLP
San Diego, California
February 26, 2010

ALNYLAM PHARMACEUTICALS, INC. Reports